Loading...
Market
First company to announce new urothelial cancer treatment post-Trodelvy withdrawal?
2
Resolution / Starting Odds
Merck & Co. • 25%
Bristol-Myers Squibb • 25%
Roche • 25%
Other • 25%
Press releases or announcements from pharmaceutical companies
Story
Gilead to Withdraw US Approval for Trodelvy in Urothelial Cancer on Friday
Oct 18, 2024, 01:00 PM
Gilead Sciences has announced its decision to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adults with locally advanced or metastatic urothelial cancer. This decision, announced on Friday, follows consultations with the FDA and the results from the TROPiCS-04 study, which did not meet the overall survival endpoint. The withdrawal specifically affects patients who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Other indications for Trodelvy remain unaffected. The drug was used in previously treated bladder cancer patients.
View original story
Similar markets
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
No new partnership • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%